To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications (NCT06553027)
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Who can join: Review the eligibility criteria below.
Location: The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Age range: 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (94 Sites)
Showing the first 25 of 94 sites.
- The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama
- University of Alabama at Birmingham ALS Clinic — Birmingham, Alabama
- Barrow Neurological Institute — Phoenix, Arizona
- Muhammad Ali Parkinson Center — Phoenix, Arizona
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- Parkinson's Research Centers of America - Orange county — Aliso Viejo, California
- Parkinson's Research Centers of America - Orange County — Newport Beach, California
- Parkinson's Research Centers of America - Palo Alto — Palo Alto, California
- CenExel Rocky Mountain Clinical Research — Englewood, Colorado
- David and Rhoda Chase Family Movement Disorders Center - Vernon — Vernon, Connecticut
- Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida
- SFM Clinical Research, LLC — Boca Raton, Florida
- K2 Medical Research — Maitland, Florida
- Renstar Medical Research — Ocala, Florida
- N1 Research LLc — Orlando, Florida
- Parkinson's Disease Center of SWFL — Port Charlotte, Florida
- University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - Brain & Spine Institute — Port Orange, Florida
- USF Parkinson's Disease and Movement Disorders Center — Tampa, Florida
- Atlanta Neuroscience Institute — Atlanta, Georgia
- University of Kansas Medical Center — Kansas City, Kansas
- University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research — Lexington, Kentucky
- Boston Clinical Trials — Boston, Massachusetts
- University of Michigan Dept. of Neurology — Ann Arbor, Michigan
- University of Michigan Hospital - Michigan Clinical Research Unit (MCRU) — Ann Arbor, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease
- Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation — Tucson, Arizona
- Parkinson's Disease Progression Study — Aurora, Colorado
- Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) — Seattle, Washington
- Automated Imaging Differentiation of Parkinsonism — Birmingham, Alabama
- Study in Parkinson Disease of Exercise — Birmingham, Alabama
Explore by condition: All Parkinson Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.